The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets?

Taking stock of the drug industry, from the lab to the medicine chest

November 11, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

adobe STAT+ | The $10 billion question: Will Pfizer hit it big with Metsera, or have regrets? The drug giant's acquisition comes with risks not only about whether Metsera's obesity drugs will be proven effective but about their competitiveness. By Elaine Chen STAT+ | China's biotech boom is being driven by a dazzling market rebound Investor optimism and state support are fueling growth in China's biotech industry as it seeks to surpass its peers in the U.S. in innovation. By Liyan Qi STAT+ | What Pfizer's Metsera deal means for biotech M&A The drug giant's triumph over Novo Nordisk in acquiring Metsera, the obesity startup, offers some hard lessons. By Matthew Herper Adobe STAT+ | U.K. releases plan to phase out animal testing in research Certain experiments will wind down in the coming years, as some scientists make the case for the continued importance of animal research. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser